Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) ...Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years;therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.展开更多
We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve comp...We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first relapse. Cases of AML secondary to myelodysplastic syndrome or myeloproliferative disorder were included. CR was achieved in 6 of 9 patients, and 2 of 6 responders became long-term survivors. No non-responders survived longer than 6 months. Toxicity was mild, and the median duration of myelosuppression was less than 30 days. Stomatitis, nausea and sepsis occurred as non-hematological adverse events. Although our sample size was too small to permit definitive conclusions, GO reinduction should be considered for patients who relapse or do not achieve CR after the first cycle of induction chemotherapy. Some AML subtypes may respond more robustly than others, and further investigation is warranted.展开更多
1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomiz...1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomized phaseⅢEORTC-GIMEMAAML-19 trial[J].J Clin Oncol,2016,34（9）：972-979.2证据水平1b。展开更多
文摘Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 monoclonal antibody conjugated to a derivative of an antitumor antibiotic, calicheamicin. GO was approved for the treatment of relapsed acute myeloid leukemia (AML) in the United States (US) in 2000. However, GO was withdrawn from the US market in June 2010, because a large-scale clinical trial failed to show additive or synergistic effects with conventional chemotherapy for newly diagnosed AML. GO is currently available only in Japan. However, several large clinical studies have demonstrated beneficial effects of GO when added to chemotherapy for AML in recent years;therefore, reconsideration of GO availability is gaining attention. Therefore, the role and efficacy of GO as monotherapy or in combination therapy for de novo or relapsed AML should be positively investigated.
文摘We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction) for patients who did not achieve complete remission (CR) after the first cycle of induction chemotherapy or at first relapse. Cases of AML secondary to myelodysplastic syndrome or myeloproliferative disorder were included. CR was achieved in 6 of 9 patients, and 2 of 6 responders became long-term survivors. No non-responders survived longer than 6 months. Toxicity was mild, and the median duration of myelosuppression was less than 30 days. Stomatitis, nausea and sepsis occurred as non-hematological adverse events. Although our sample size was too small to permit definitive conclusions, GO reinduction should be considered for patients who relapse or do not achieve CR after the first cycle of induction chemotherapy. Some AML subtypes may respond more robustly than others, and further investigation is warranted.
基金support from the UK National Institute of Health Research(NIHR)Biomedical Research Centre and the Ministry of Science and Technology of China (84000-51200002)funded by an internal grant of the Iuliu Hatieganu University-School of Doctoral Studies+4 种基金funded by an internal grant of the Iuliu Hatieganu University-School of Medicinesupported by agrant from the Romanian National Ministry of Research,Innovation and Digitalization(PN-Ⅲ-P4-ID-PCE-20201118within PNCDI Ⅳ,Projects for Exploratory MedicineProjects for Exploratory Medicine-PCE 225/202)a national grant awarded to Young Research Teams(PN-Ⅲ-PI-1.1-TE-20190271)an international collaborative grant of the European Economic Space between Romania and Iceland 2021-2023:(Cooperation strategy for knowledge transfer,internationalization and curricula innovation in the field of research education at the 3rd level of study-AURORA)
文摘1文献来源Amadori S,Suciu S,Selleslag D,et al.Gemtuzumab Ozogamicin versus best supportive carein older patients with newly diagnosed acute myeloidleukemia unsuitable for intensive chemotherapy：Results of the randomized phaseⅢEORTC-GIMEMAAML-19 trial[J].J Clin Oncol,2016,34（9）：972-979.2证据水平1b。
